AKV9 / Akava Therap - LARVOL DELTA

Akava Therapeutics, Inc. shares recent data suggesting that AKV9 acts on a common mechanism involved in both Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) (Businesswire) - "Akava Therapeutics, Inc. is pleased to announce the publication in PNAS of results demonstrating benefits of its lead small molecule drug AKV9 for the treatment of Alzheimer’s disease (AD)....The efficacy of AKV9 as a protein aggregation inhibitor was demonstrated at Northwestern University using rat hippocampal cell cultures. The addition of amyloid beta oligomers (AβO) to the cultures quickly formed aggregates. However, the addition of AKV9 before the addition of AβO reduced the amount of protein build up within the cells and along branches and dendrites. A small proof of concept study in a mouse model of AD was conducted with favorable results."

Preclinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis

ALS Drug Shows Promise for Alzheimer's in Animal Study (Mirage News) - "The study was published last month (March 3) in the Proceedings of the National Academy of Sciences. The paper demonstrates the drug's efficacy in cellular cultures and a small mouse study....They administered an oral dose of NU-9 to a mouse model of Alzheimer's disease and found the animals' performance on memory tests improved. In promising follow-up studies, the team also found NU-9 reduces brain inflammation associated with Alzheimer's disease....The team also plans to explore the effectiveness on NU-9 in other neurodegenerative diseases, like Parkinson's disease and Huntington's disease."

Preclinical • Alzheimer's Disease • Huntington's Disease • Parkinson's Disease

Akava Therapeutics, Inc. congratulates SAB Chair Dr. Hande Ozdinler, Founder Dr. Richard B. Silverman, and Dr. William Klein on their recent grant of $7.3 million from the National Institute on Aging to investigate AKV9 in neurodegenerative diseases (Businesswire) - "Akava Therapeutics, Inc...celebrates the procurement of a grant totaling $7.3 million from the National Institute on Aging...to investigate the protein aggregation inhibitor, NU-9 (AKV9), its mode of action, and impact on Alzheimer’s disease (AD) and frontotemporal dementia (FTD)."

Financing • Alzheimer's Disease • CNS Disorders • Dementia

Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral Sclerosis (Businesswire) - "Akava Therapeutics, Inc...celebrates a significant achievement. On July 3rd, the U.S. Food and Drug Administration cleared Akava’s Investigational New Drug (IND) application for the treatment of amyotrophic lateral sclerosis (ALS) to proceed with a Phase I first-in-human study in healthy subjects using Akava’s investigational new drug, AKV9 (formerly NU-9). The study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of AKV9....In preclinical models, unlike other drugs, AKV9 was found to act on multiple cellular degeneration pathways that are critical to the progression of the disease, by inhibiting protein aggregation, restoring cellular integrity, and improving the health of the mitochondria, endoplasmic reticulum, apical dendrites, and axons."

IND • New P1 trial • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders